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Plasma total cysteine (tCys) is strongly and independently associated with obesity in large human cohorts, but whether the association is causal is unknown.
Dietary cyst(e)ine increases weight gain in some rodent models. We investigated the body composition, metabolic rate and metabolic phenotype of mature C3H/
HeH mice assigned to low-cystine (LC) or high-cystine (HC) diets for 12 weeks.
Compared to LC mice, HC mice gained more weight (P=.004 for 12-week weight gain %), with increased fat mass and lean mass, and lowered O2
consumption and CO2 production by calorimetry. The HC mice had 30% increase in intestinal fat/body weight % (P=.003) and ∼twofold elevated hepatic
triglycerides (P=.046), with increased expression of hepatic lipogenic factors, peroxisome proliferator-activated receptor-γ and sterol regulatory element
binding protein-1. Gene expression of both basal and catecholamine-stimulated lipolytic enzymes, adipose triglyceride lipase and hormone-sensitive lipase was
inhibited in HC mice adipose tissue. The HC mice also had elevated fasting glucose (7.0 vs. 4.5 mmol/L, Pb.001) and a greater area under the curve (Pb.001) in
intraperitoneal glucose tolerance tests, with enhanced expression of the negative regulator of insulin signaling, protein tyrosine phosphatase-1B, in liver and
adipose tissue.
Overall, high cystine intake promotes adiposity and an adverse metabolic phenotype in mice, indicating that the positive association of plasma tCys with
obesity in humans may be causal.
© 2012 Elsevier Inc. Open access under CC BY license.Keywords: Cysteine; Cystine; Sulfur amino acids; Adiposity; PTP1b; Metabolic rate; Energy expenditure; Glucose tolerance; Insulin sensitivity1. Introduction
Cysteine is a proteinogenic sulfur amino acid that is associated
with cardiovascular disease [1,2] and metabolic syndrome [3] in
humans. Cysteine is obtained from diet and synthesized from the
methionine product, homocysteine, by transsulfuration, with
cystathionine as an intermediate [4]. In addition to protein synthesis,
cysteine is utilized in synthesis of taurine and coenzyme A, and the
antioxidant glutathione (Supplementary Figure 1) [4]. Due to its
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sulfhydryl compounds.
Plasma total cysteine (tCys) concentrations consistently correlate
with body mass index (BMI), fat mass and odds of obesity in large
human studies [5,6], and higher consumption of the cysteine
precursor methionine is associated with increased BMI and diabetes
prevalence [7]. Phenotypes of genetic syndromes affecting cysteine
metabolism (discussed in Ref. [6]) suggest that the relation of tCys
with obesity reflects a causal role for cysteine in regulating body
weight. In N5000 men and women, tCys was associated with waist–
hip ratio, suggesting a relation between cysteine and increased
visceral fat [5]. The mechanism underlying the association of tCys
with human adiposity is unknown. In vitro L-cysteine inhibits rat
adipocyte lipolysis in concentrations of 0.1–0.5 mmol/L, over 10 times
the circulating concentrations of free cysteine in humans [8]. Direct in
vivo evidence implicating cysteine in promoting obesity or metabolic
risk is lacking.
Indirect evidence on involvement of cysteine in body fat
regulation and glucose homeostasis comes from effects of dietary
methionine restriction, which decreases plasma tCys by nearly one
half [9,10]. Two different low-methionine dietary rodent models
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metabolic rate, with decreased plasma glucose and insulin concen-
trations [11,12]. The hypermetabolic phenotype in both models is
linked to profound suppression of hepatic stearoyl CoA desaturase-1
(SCD-1), a δ-9 fatty acid desaturase regulated by sterol regulatory
element binding protein-1 (SREBP-1) andwhich has emerged as a key
regulator of lipid and energy metabolism [13]. Genetic SCD-1
deficiency in mice is linked to resistance to obesity [14] and improved
insulin sensitivity [14], partly mediated via suppression of the
negative regulator of insulin signaling, protein tyrosine phospha-
tase-1B (PTP-1B) [15].
In contrast to low-methionine diets, cysteine and cystine
supplementation in rodent models increases weight gain despite
reduced or unchanged food intake [16–18]. This pattern is consistent
with early observations that sulfur amino acid content of diets
correlates with food conversion efficiency (g weight gain/g food
consumed) [19], and suggests an influence of cysteine on metabolic
rate. The body composition, energy expenditure and metabolic
features of cyst(e)ine-supplemented rodents are, however, unknown.
We therefore investigated the metabolic phenotype associated with
high vs. low cystine intakes in mice.
2. Methods
2.1. Animal husbandry and diets
Animal studies were conducted using guidelines issued by the Medical Research
Council in “Responsibility in the Use of Animals for Medical Research” (July 1993). Mice
were kept in accordance with UK Home Office welfare guidelines and project license
restrictions under controlled light (12-h light and 12-h dark cycle; dark 7 p.m.–7 a.m.),
temperature (21°C±2°C) and humidity (55%±10%) conditions. They had free access to
water (10 ppm chlorine) and a commercial diet [SDS Rat andMouse No.3 Breeding diet
(RM3)] containing 3.36 g% fat, 22.45 g% protein and 71.21 g% carbohydrate.
Male C3H/HeH mice were maintained on RM3 diet from weaning till maturity. At
10 weeks of age, mice were shifted to either a low-cystine (LC) or high-cystine (HC)
diet consisting of 10% casein protein diet with (HC) or without (LC) addition of 0.8 g% L-
cystine for an experimental duration of 12 weeks. The LC diet had a calculated L-cystine
content of 0.07 g%, methionine content of 2.9 g% and more than adequate protein
content for maintenance requirements of adult mice [20] (Table 1) (D10012M/ AIN-
93MModified Rodent Diet, Research Diets, New Brunswick, NJ, USA). A third groupwas
continued on the Breeding RM3 diet (standard diet; SD) for monitoring of weight gain
compared to the LC and HC groups.
Phenotyping tests were performed according to the European Phenotyping
Resource for Standardised Screens from EUMORPHIA standardized protocols as
described at http://empress.har.mrc.ac.uk. Unless otherwise stated, phenotyping
tests are described and reported with reference to the number of weeks on the
experimental diets.
2.2. Body composition
Body mass was measured each week from 10 weeks of age on scales calibrated to
0.01 g. Analysis of body composition was performed by dual-energy x-ray
absorptiometry (DEXA) scanning using the Lunar PIXImus Mouse Densitometer at
weeks 0, 4, 8 and 12 of the experiment (Wipro GE Healthcare, Madison, WI, USA).
Before DEXA analysis, a general anesthetic (100 mg/kg of ketamine, Pfizer; 10 mg/kg ofTable 1
Composition of the experimental diets
Ingredient, g% LC HC
Casein 10 10
Contains: l-cystine 0.07 0.07
Contains: methionine 0.29 0.29
L-Cystine (supplemented) 0 0.8
Cornstarch 53.7 52.9
Maltodextrin 10 12.5 12.5
Sucrose 10 10
Soybean oil 4 4
Total protein 10 10.8
Total carbohydrate 77 76.2
Total fat 4 4
Other constituents common to both diets include cellulose (5 g%), mineral mix (3.5 g%),
vitamin mix (0.1 g%) and choline bitartrate (0.25 g%). Vitamin and mineral mixes were
formulated according to American Institute of Nutrition guidelines [21].xylazine, CEVA) was administered via intraperitoneal injection. After analysis, mice
were revived by subcutaneous injection of atipamezole (1 mg/kg; Antisedan, Pfizer)
and left to recover in a 37°C incubator for 1 h. Terminal dissection and measurement of
fat pad weights were also performed.
2.3. Food consumption, plasma, liver and urinary parameters
At week 10, mice were placed in metabolic Techniplast cages with free access to
water and food. Food consumption was measured by weighing. Urine was collected
after 24 h in metabolic cages, and urinary catecholamines were measured using a 3-
CAT Epinephrine, Norepinephrine, Dopamine enzyme-linked immunosorbent assay
(ELISA) (Demeditec, Kiel-Wellsee, Germany) and were standardized against creati-
nine. Plasma leptin, insulin, adiponectin and glucagon levels were measured using a
mouse endocrine MILLIPLEX kit (MILLIPLEX MAP, Millipore, Billerica, MA, USA) and a
Bio-Plex 200 system (Bio-Rad, Hemel Hempstead, UK). At week 12, mice were fasted
for 6 h during the light phase and given a lethal dose of anesthetic (200 mg/kg of
ketamine, Vetalar, Pfizer, Kent, UK; 10 mg/kg of xylazine, Sedaxylin, CEVA,
Buckinghamshire, UK) via intraperitoneal injection, and blood was collected by cardiac
puncture. Plasma concentrations of glucose, lipids and albumin, and urine creatinine
were measured on an AU400 (Olympus UK) as described [22,23]. Liver samples were
homogenized in 5% Triton-X100 in dH2O, heated to above 80°C, cooled and heated
again to solubilize triglyceride into solution. Liver lysate triglyceride, glycerol and free
fatty acids were analyzed as per plasma samples [22].
2.4. Plasma sulfur amino acid and glutamate measurements
Liquid chromatography tandem mass spectrometry (LC-MS/MS) was used to
analyze total homocysteine (tHcy), methionine, cystathionine, tCys and total
glutathione (tGSH) [24].
2.4.1. Analysis of taurine and glutamic acid by LC-MS/MS
Plasma (25 μl) wasmixedwith 25 μl internal standard solution containing 50 μmol/
L [1,2-13C2]taurine (Isotec, Sigma Aldrich, Miamisburg, OH, USA) and 30 μmol/L 2H3-DL-
glutamic acid (Cambridge Isotope Laboratories Inc., MA, USA) in 30 mmol/L
ammonium formate, pH 3.2. Afterward, 125 μL methanol was added for protein
precipitation, followed by centrifugation at 11,000g for 10 min. The supernatant was
transferred to new vials and stored at 2°C until analysis. For separation, a Discovery HS
F5 column (150×4.6 mm internal diameter, 3.5 μm pore size and a 2-μm precolumn
filter, Sigma-Aldrich, Bellefonte, USA) was used. A Gilson 215 Autosampler (Middleton,
WI, USA) was used to inject the sample (20 μL) onto the column, which had been
equilibrated with a mobile phase (Perkin Elmer Series 200 Micro Pumps, Norwalk, CT,
USA) composed of methanol and 30 mmol/L ammonium formate, pH 3.5, 60%:40% (v:
v) at a flow rate of 1 mL/min. Separation was achieved by isocratic elution after 1.88
min for taurine, and 2.4 min for glutamic acid. Detection of taurine and glutamic acid
was by multiple reaction monitoring on an API 365 PE SCIEX LC-MS/MS (Toronto,
Canada) with Enhanced Performance system EP10+ (Bolton, Ontario, Canada),
operating in the positive ion mode. Data acquisition and analysis were performed by
Analyst 1.4.1 (MDS SCIEX, Applied Biosystems, Concord, Ontario, Canada). Interassay
coefficient of variation for taurine and glutamic acid was 3.5% and 10.5%, respectively.
2.5. Metabolic rate
Metabolic rate was measured at week 4 using indirect calorimetry (Oxymax;
Columbus Instruments, OH, USA) to determine oxygen consumption (VO2), carbon
dioxide production (VCO2) and respiratory exchange ratio (RER). The VO2 and VCO2
were normalized to body mass and to lean and fat tissue mass derived from DEXA
analysis.
2.6. Intraperitoneal glucose tolerance test
Each mouse was fasted overnight (16 h) to establish baseline glucose level “T0”
(time zero). Mice were weighed, and a blood sample was collected from the tail vein
after administration of local anesthesia (EMLA cream) using lithium-heparin Microv-
ette tubes (Sarstedt, Nümbrecht, Germany). Each mouse then received an intraper-
itoneal injection of 2 g glucose/kg body weight (20% glucose in 0.9% NaCl). Subsequent
blood samples were taken (at 60 and 120min at week 7 or at 10, 20 and 20min at week
11) after glucose injection. Plasma glucose was measured using an Analox Glucose
Analyser GM9. Plasma insulin was measured using a Mercodia ultrasensitive mouse
ELISA (Mercodia, Sweden). Area under the curve analysis was performed using
GraphPad Prism version 5.02 for Windows.
2.7. Gene expression profiling
Total RNA was prepared from liver, gastrocnemius skeletal muscle and subcuta-
neous white adipose tissue (WAT) of LC (n=10) and HC (n=10) mice after 12 weeks
on the diets following a 6-h light-phase fast.
Liver RNA was prepared using an RNeasy Plus Mini Kit (Qiagen, USA). Skeletal
muscle RNA was prepared using an RNeasy fibrous Mini Kit, and WAT was prepared
using an RNeasy Lipid Tissue Mini Kit (Qiagen, USA). The RNA concentration was
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The ratio of absorbance at 260 and 280 nm was used to assess the purity of RNA. The
extracted RNA was stored at −80°C. cDNA was prepared using Superscript III reverse
transcriptase (Invitrogen). Quantitative polymerase chain reaction (PCR) was
performed using TaqMan Gene Expression Assay reagents and TaqMan FAM dye-
labeled probes (Applied Biosystems Inc., USA) using an ABIPRISM 7700 Fast Real-Time
PCR System (Applied Biosystems Inc., USA). Data were normalized to expression of the
endogenous housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
and analyzed by the comparative ΔΔCT method to determine the difference between
LC and HC groups.
2.8. Statistical methods
Data are expressed as mean±S.E.M. Comparison between groups was performed
with a Student's t test for independent samples using Microsoft Excel 2003 for
Windows. All tests were two-tailed, and Pb.05 was considered statistically significant.
3. Results
3.1. Weight gain
The HC group gained consistentlymore weight than LC over the 12
weeks of the study (Fig. 1). At week 12, the percent weight change
from baseline in the HC group was 33% higher than in the LC group
(P=.004).
Body weight in LC and HC groups over the 12 weeks matched or
exceeded the standard diet group (Fig. 1), confirming that the protein
intake in LC and HC groups was adequate for maintenance require-
ments in these mature mice as recommended by Tobin et al. [20].
Subsequent analysis was restricted to comparing the LC and HC
groups.
3.2. Body composition and plasma and hepatic lipids
Total fat mass and lean mass measured by DEXA were similar in
HC and LC groups at baseline, but were significantly higher in HC at
weeks 4, 8 and 12 (Fig. 2A). Total fat mass as a percent of body weight
remained similar in both groups, whereas peri-intestinal fat mass
dissected at the termination of the study (week 12) was ∼30% higher
in HC whether normalized to total fat mass or body weight (P=.003)
(Fig. 2B, C). There was no difference in the weights of epididymal or
brown fat pads. The HC mice also had elevated hepatic triglycerides
and free fatty acids at week 12 (Fig. 2D).
At week 12, HC mice had higher plasma low-density lipoprotein
cholesterol (LDL-C) and triglycerides than LC mice. Plasma glycerol
was significantly reduced in HC mice, suggesting decreased lipolysis,
but there was no difference in free fatty acid concentrations (Table 2).25
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Fig. 1. Body weight varies with dietary cystine. (A) Body weight of male mice on an LC diet (n=
SD (n=10weeks 0–4, n=5weeks 5–12). Body weight in HCmice is significantly higher than th
that in SD mice at baseline (P=.019) and at all other time points (Pb.05). Body weight in LC is
gain after 12 weeks in the groups specified above. Percent body weight gain after 12 weeks is 3
from that in LC or HC group (P≥.23). Data are expressed as mean±S.E.M.Similarly, there was no difference in plasma total cholesterol, high-
density lipoprotein cholesterol (HDL-C) or leptin between the groups
(Table 2).
A consistent increase in bone mineral content (BMC) measured by
DEXA was seen in HC relative to LC, which reached statistical
significance at week 12. There was no difference in bone mineral
density (BMD) at the four time points examined (Fig. 2E, F).
3.3. Metabolic rate
The VO2 and VCO2 measured at week 4 were markedly lower in
the HC compared to the LC group during both the light and dark
phases (P≤.001 for sum of both phases), whether normalized to body
weight (Fig. 3A-D) or to lean mass or fat mass measured by DEXA at
week 4 (data not shown). The RER, however, remained similar in both
groups, suggesting that dietary cystine suppresses metabolic rate but
does not influence the type of substrate (fat or carbohydrate) utilized
for energy (Fig. 3E).
3.4. Food/water intake and urine parameters
Measurement of 24-h cumulative food intake inmetabolic cages at
week 10 showed that, although no significant difference was
observed, HC showed a trend towards higher food consumption,
even when adjusted for their higher body weight (Fig. 3F). Other
metabolic cage parameters, namely, water consumption and urine
output, were similar in both groups (data not shown).
Urine collected at week 10 was used to measure glucose,
adrenaline and noradrenaline. There were no glucosuria in either
group and no difference in urinary catecholamines between the LC
and HC groups (data not shown).
3.5. Glucose homeostasis
Consistent with the increased visceral fat %, the HC group
exhibited impaired glucose tolerance compared to LC. A 120-min
intraperitoneal glucose tolerance test (IPGTT) performed at week 7
showed elevated 16-h fasting glucose in the HC group (7.0 vs. 4.5
mmol/L, Pb.001), which remained significantly higher 60 and 120min
postinjection (Fig. 4A). A 30-min IPGTT at week 11 similarly showed
reduced glucose tolerance in HC mice as evidenced by raised plasma
insulin and glucose at baseline and at 20 and 30 min postinjection
(Fig. 4B), suggesting the presence of insulin resistance.1 12
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mice at weeks 7, 11 and 12. There was no difference in plasmaTable 2
Effect of dietary cystine on plasma metabolic parameters
LC (n=12) HC (n=11) P value
TG, mmol/L 1.14±0.09 1.56±0.14 .014
FFA, mmol/L 1.07±0.06 0.98±0.07 .34
Glycerol, μmol/L 613±34 492±30 .014
Total-C, mmol/L 5.42±0.23 6.13±0.32 .084
HDL-C, mmol/L 3.60±0.32 3.41±0.21 .64
LDL-C, mmol/L 0.56±0.03 0.88±0.14 .026
Glucose, mmol/L 16±1 16±2 .97
Albumin, g/L 27.9±0.5 25.9±0.8 .22
Leptin, ng/mL 13.2±2.8 17.0±2.8 .35
In 6-h fasting adult male mice after 12 weeks on the diets. Data are given as
mean±S.E.M. TG, triglycerides; FFA, free fatty acids; Total-C, total cholesterol;
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol.glucagon or adiponectin (measured at week 12) between the groups
(Fig. 4C, D, E).3.6. Plasma sulfur amino acids
Plasma methionine, tHcy, cystathionine, tCys and tGSH were
measured at baseline and after 1, 2, 3, 4, 7 and 12 weeks on the diets,
while taurine and glutamate were assayed at baseline and at weeks 1,
2, 3 and 12.
There was no difference in plasma tCys between the HC and LC
groups throughout the study, which was unexpected given the
increase in dietary cystine in the HC group and similar food intake.
However, plasma levels of taurine, a downstream product of cysteine,
were consistently higher in the HC group at all time points examined
apart from baseline, being ∼40% higher after 12 weeks on the diet
(Fig. 5D).
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persisted throughout the study, together with decrease in cystathio-
nine (Fig. 5C). There was no consistent difference in tGSH, methionine
or glutamate between the groups.
3.7. Gene expression profile
We compared the expression pattern of genes implicated in
glucose, lipid and energy metabolism in liver, subcutaneous WAT and
muscle in HC vs. LC mice, with focus on genes that have shown
changes in response to methionine restriction [25].
InWAT, both the basal lipolytic enzyme adipose triglyceride lipase
(ATGL, Pnpla2) and catecholamine-stimulated hormone sensitive
lipase (HSL, Lipe) were suppressed in HC compared to LC, with no
effect on the β3 adrenoceptor (Adrb3) (Fig. 6A). There was no effect of
dietary cystine on lysosomal acid lipase (LAL, Lipa), which mainly
mediates hydrolysis of cholesterol esters, or lipoprotein lipase (LL,
Lpl), which hydrolyses triglycerides in circulating lipoproteins for
uptake by adipose tissue (Fig. 6A).
In WAT, high dietary cystine also induced the transcription
factors peroxisome proliferator-activated receptor-γ (PPAR-γ)
(Pparg) and SREBP-1 (Srebf1), but had no significant effect onexpression of the SREBP-target genes SCD-1 or fatty acid synthase
(FAS, Fasn). Consistent with the reduced glucose tolerance in HC
mice, the negative regulator of insulin signaling, PTP-1B (Ptpn1),
was up-regulated by ∼fourfold in these mice compared to LC group
(Fig. 6A).
Similar to WAT changes, hepatic PPAR-γ and PTP-1B gene
expression was also up-regulated in HC mice, with no difference in
SCD-1 or SREBP-1 expression between HC and LC mice (Fig. 6B).
However, in contrast toWAT, hepatic PPAR-γ co-activatorα (PGC-1α,
Ppargc1a) was induced by cystine feeding.
To further explore the mechanism of the hypometabolic
phenotype of HC mice, we investigated the expression of genes
involved in oxidative phosphorylation and energy metabolism in
skeletal muscle. The nuclear encoded subunit of cytochrome c
oxidase, cyclooxygenase 4 (COX 4, COX4), was significantly
suppressed (P=.037) in HC mice by ∼40%, while uncoupling
protein-3 (UCP-3) was induced, with no difference in UCP-2 (Fig.
6C). In contrast to WAT and liver changes, there was no significant
difference in muscle PTP-1B expression. There was also no change in
expression of SCD-1 or of carnitine palmitoyl acyltransferase 1b
(CPT-1b), the rate-limiting enzyme in long-chain fatty acid oxida-
tion in muscle mitochondria (Fig. 6C).
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We compared the metabolic and anthropometric phenotypes of
mice with low and high cystine intakes. High dietary cystine
decreased metabolic rate, lowered insulin sensitivity and increased
visceral fat deposition, in conjunction with changes in expression of
several genes involved in lipid and glucose metabolism. Cystine
supplementation enhanced total fat mass, lean mass and BMC, withno effect on BMD. Fasting plasma tCys and tGSH did not increase, but
plasma taurine was higher in the cystine-supplemented group
throughout the study.
4.1. Dietary cystine and body composition
Cystine feeding enhanced fat mass and lean mass growth, with no
net change in body fat % However, body fat distribution was shifted
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body fat was increased, with increased hepatic triglycerides.
Consistent with these findings, rats with decreased plasma tCys
secondary to methionine restriction have a 30% reduction in visceral
fat % [9].
The mechanism of increased fat mass needs to be further
investigated, but suppression of expression of both HSL and ATGL in
HC mice, if translated into decreased levels of these enzymes, could
suggest that high cystine intakemay inhibit adipose tissue lipolysis, as
seen in vitro in response to cysteine [8]. Decreased expression of HSL
and ATGL is a feature of human obesity and insulin resistance [26,27],
although it is debated whether suppression of lipolysis is the cause or
a consequence of the obese state [28]. Another factor underlying
increased adiposity in the HC group is decreased energy expenditure.
4.2. Dietary cystine and metabolic rate
Dietary cystine substantially suppressed metabolic rate. In line
with this, dietary cyst(e)ine increases weight gain in the face of
reduced [18] or unchanged [17] food intake, suggesting that cysteine
affects the energy expenditure arm of the energy balance equation.
Neither urinary catecholamines nor WAT B3-adrenoceptor expres-
sion was altered in HC mice, suggesting that the reduced metabolic
rate is mediated by local tissue changes rather than alteredsympathetic signal. There was also no appreciable change in physical
activity, but that was not formally measured. However, as the
metabolic rate differences were noted in both the dark (active) and
light phases, physical activity is unlikely to be a major contributor to
these differences.
Hepatic SCD-1 suppression is linked to hypermetabolic pheno-
types associated with dietary restriction of the cysteine precursor
methionine [12,25], and responds to cysteine supplementation of
methionine-restricted rats [29]. We therefore hypothesized that the
effect of cystine on metabolic rate in our model could be mediated by
SCD-1. However, we did not note any changes in SCD-1 expression in
liver, muscle or adipose. This does not exclude that SCD-1 protein
levels may be altered, as seen in methionine restriction [25]. There
was similarly no consistent effect of HC on expression of uncoupling
proteins. The HC mice, however, featured enhanced PTP-1B expres-
sion by fourfolds in WAT and twofolds in the liver. Protein tyrosine
phosphatase-1B, a phosphatase physiologically involved in terminat-
ing the insulin signaling cascade [30], is overexpressed in obesity and
insulin resistance [31]. Notably, PTP-1B is also involved in regulation
of energy expenditure, and PTP-1B-deficient mice feature increased
energy expenditure and decreased adiposity independent of uncou-
pling protein expression [32]. This suggests that PTP-1B induction
may be implicated in the decreased energy expenditure and increased
adiposity of HC mice, as well as in their lowered insulin sensitivity, as
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taurine, have both been found in animalmodels to decreasemetabolic
rate [33,34]. Thus, an effect of these products on metabolic rate in HC
mice cannot be excluded, given their elevated plasma taurine.
4.3. Dietary cystine and glucose/lipid homeostasis
Dietary cystine adversely affected fasting plasma glucose and
insulin, and 30- and 120-min intraperitoneal glucose tolerance. We
postulate that this is related to the enhanced expression of hepatic
and WAT PTP-1B, a negative regulator of insulin signaling [30].
Hepatic PTP-1B overexpression produces not only insulin resistance
but also hypertriglyceridemia resulting from induction of hepatic
SREBP-1 [35,36]. This parallels the SREBP-1 overexpression and
increased plasma triglycerides observed in the HC group. Hepatic
PTP-1B overexpression is also implicated in assembly and secretion of
apolipoprotein B (ApoB)-containing lipoproteins [37], which may
explain the cystine-induced elevation of the ApoB-related LDL-C in
the present study. Increased plasma ApoB in response to a high-
cystine diet has been previously reported [38], as well as increased
hepatic and plasma total cholesterol [39]. In humans, plasma tCys
positively correlates with plasma total cholesterol [40] and fasting
serum LDL-C and ApoB [1]. Thus, combined evidence from human and
rodent studies suggests that increased cystine availability promotes
an insulin-resistant and dyslipidemic state.In apparent contradiction to our findings, L-cysteine supplemen-
tation improved glucose tolerance in a rat model of type 2 diabetes
[41], and a cysteine-rich protein supplementation alleviated sucrose-
induced insulin resistance [42]. However, these effects were observed
in diseased models rather than in normal mice as in our study. Few
studies have examined the effect of cysteine administration on
glucose homeostasis in conditions of normal glucose tolerance. In one
study, glucose tolerance deteriorated in rats following a single
intravenous injection of cysteine [43]. In the present study, it is likely
that the increased visceral fat mass contributed to the insulin
resistance phenotype. Increased intrahepatic fat, as observed in HC
mice, was shown to be an even better predictor of metabolic
deterioration than visceral fat [44].
4.4. Dietary cystine and plasma sulfur amino acids
In humans, plasma tCys is a strong predictor of BMI and fat mass
[5,6,40], but determinants of plasma tCys variability are yet to be
investigated. Epidemiologic predictors, rather than causal biologic
determinants of tCys, have been reported [40] and include blood
pressure, plasma cholesterol and BMI. Cysteine and its precursor,
methionine, are ingested in diet, but there is some evidence to suggest
that dietary cyste(i)ne intake may not be an important determinant of
tCys. In a recent study in 812 healthy women, plasma tCys was
unrelated to dietary intakes of either cystine or methionine [45]. A
similar observationwasmade in cats fed different levels of cysteine [46].
One factor explaining the lack of association of plasma tCyswith cystine
intake may be the central role of the liver in disposing of excess dietary
cysteine through conversion to taurine [47]. Indeed, in the present
study, the HC group did not have higher plasma tCys but had higher
plasma taurine throughout the study. Similarly, increasing dietary
cystine intake in growing rats [48] raised plasma taurine concentrations
but didnot raise plasmacystine. On the other hand, Kawakami et al. [16]
reported modest increases in plasma tCys in response to supplemen-
tation of cysteine in its reduced form. One reason for the discrepancy
with our findings besides the different formof cysteine supplemented is
that Kawakami et al. used nonfasting samples,whichmay have enabled
the detection of a transient postprandial rise in tCys.
Dietary cystine supplementation had a minimal effect on plasma
concentrations of other sulfur amino acids, with the notable exception
of the consistently higher plasma tHcy in the HC group. We speculate
that this could be explained by inhibition of transsulfuration, as
evidenced also by the decreased plasma concentrations of the first
transsulfuration product, cystathionine. Finkelstein et al. [49] dem-
onstrated suppression of transsulfuration and of cystathionine
formation when supplementing rats on a methionine-free diet with
cystine, in a recognized “methionine-sparing effect of dietary cystine.”
5. Summary
In summary, a high-cystine diet in adult mice increased growth
and visceral fat, suppressed metabolic rate and decreased glucose
tolerance, suggesting a central role of cysteine in metabolic
regulation. Given the established link of plasma tCys with obesity
[5,6] and metabolic syndrome [3] in epidemiologic studies, the role of
increased cysteine availability in pathogenesis of human obesity and
insulin resistance should be further investigated.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.jnutbio.2010.12.009.
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